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Abstract The cytokine macrophage migration inhibitory factor
(MIF) is inducibly secreted by immune cells and certain other
cell types to critically participate in the regulation of the host
immune response. However, MIF does not contain a N-terminal
signal sequence and the mechanism of MIF secretion is un-
known. Here we show in a model of endotoxin-stimulated
THP-1 monocytes that MIF does not enter the endoplasmatic
reticulum and that MIF secretion is not inhibited by monensin
or brefeldin A, demonstrating that MIF secretion occurs via a
non-classical export route. Glyburide and probenicide but not
other typical inhibitors of non-classical protein export strongly
block MIF secretion, indicating that the export pathway of MIF
involves an ABCA1 transporter.
* 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Macrophage migration inhibitory factor (MIF) is a pleio-
tropic multifunctional cytokine with a mostly proin£amma-
tory spectrum of action in the host immune response. As
such, MIF is a critical mediator of a number of immune
and in£ammatory conditions (reviewed in [1^3]). A causal
and pivotal role for MIF has been best characterized in the
pathogenesis of bacterial septic shock [4], rheumatoid arthritis
[5] and tumorigenesis [2]. In these diseases, MIF is released
from the involved in£ammatory cells and numerous studies
applying neutralizing anti-MIF antibodies have shown that
released circulating MIF is critical for MIF’s immunologic
and in£ammatory e¡ects [6^11].
MIF is exceptional among cytokines, as it has several func-
tions outside the immune system [3]. MIF can act as a gluco-
corticoid antagonist and endocrine factor [9,11], it has cata-
lytic properties [12,13] and regulates cellular activity through
the coactivator JAB1/CSN5 [14] and the cell surface protein
CD74/Ii chain [15]. Thus, besides possibly having intracellular
functions, the former ¢ndings in conjunction with the data on
antibody neutralization of circulating MIF have clearly dem-
onstrated that MIF is e¡ectively secreted upon stimulation.
Speci¢c secretion of MIF can be induced by a variety of
stimuli, including in£ammatory stimuli such as endotoxin
(LPS, lipopolysaccharide) and tumor necrosis factor [16], as
well as hormones such as corticosteroids [11], adrenocortico-
trophic hormone (ACTH) [17], and angiotensin II [18]. MIF
secretion is not limited to immune cells but can also be in-
duced in endocrine cells and certain epithelial cells [3]. Unlike
for most cytokines, for which expression is tightly regulated
by stimulation, substantial levels of preformed MIF are found
in several cell types, indicating that secretion of MIF could be
due to an enhancement of MIF expression and de novo pro-
tein synthesis but could also be caused by an induction of a
release from pre-existing MIF stores. MIF release from both
origins was shown under conditions of LPS stimulation to
occur in corticotrophic pituitary cells [9,17] and in cultured
myotubes [19].
As the MIF gene does not encode for an N-terminal signal
sequence for the translocation into the endoplasmic reticulum
(ER) and because cell staining analysis has indicated that in
addition to the cytosol, where MIF is predominantly local-
ized, MIF could only be detected in small vesicles [17,20], the
nucleus [21,22], and pinched-o¡ vesicles outside of cells [20], it
has been suggested that MIF secretion may occur by a non-
classical secretion pathway. However, no biochemical study
has yet been undertaken to systematically investigate this sug-
gestion. In particular, the mechanism of MIF secretion fol-
lowing in£ammatory or immunologic stimulation has not yet
been studied.
Soluble secretory proteins such as hormones and cytokines
are usually secreted by the so-called classical or ER/Golgi-
dependent secretion pathway [23]. However, a study by Ru-
bartelli and coworkers ¢rst demonstrated for a mammalian
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secretory protein that the cytokine interleukin-1L (IL-1L) is
not secreted by a classical secretion pathway [24]. Since then,
it has become more apparent that a number of soluble pro-
teins are secreted in an ER/Golgi-independent manner. Secre-
tion of these proteins does not seem to occur by a single
pathway; rather, diverse distinct mechanisms appear to
underly the release of these proteins. Because no unifying
transport concept has been identi¢ed, these processes have
been collectively termed non-classical protein secretion or pro-
tein export to distinguish them from the classical ER/Golgi-
mediated pathway. To date, more than 20 proteins have been
identi¢ed that are secreted by non-classical export. While
some of them are typical extracellular mediators such as IL-
1K, IL-1L, or the ¢broblast growth factors FGF-1 and FGF-
2, others have previously been viewed as typical intracellular
proteins. The enzyme thioredoxin (Trx), gene-regulating pro-
teins such as the transcription factor Engrailed homeoprotein
isoform 2, or the chromatin-binding protein high-mobility
group binding protein-1 belong to this latter class of non-
classically secreted proteins. Both stimulated and apparently
uninduced secretion was observed to result in the release of
these factors. While non-classically secreted proteins belong to
diverse structural classes of proteins and while the secretion
pathways taken and the inducing stimuli are diverse, non-
classically secreted proteins generally do not have a N-termi-
nal signal sequence. They are therefore also referred to as
leaderless secretory (LLS) or signal peptide-less proteins. Evi-
dence on the secretion of LLS proteins and on the potential
export routes involved was recently summarized in a compre-
hensive review [25].
Due to its pivotal role as a mediator of Gram-negative
septic shock [9^11], MIF production has been best studied
in cellular models of LPS stimulation. Although MIF was
initially discovered as a T-cell factor acting on monocytes/
macrophages [26], it was later realized that the monocyte/mac-
rophage is the most important source of MIF in vivo [16].
MIF is potently secreted from monocytes/macrophages fol-
lowing LPS stimulation and, once released, participates in
the host in£ammatory response to the bacterial toxin
[9,10,16]. We therefore elected a cellular model of LPS-stimu-
lated monocytes to investigate the secretion mechanism of
MIF in detail and to experimentally address the possibility
that MIF could be secreted by a non-classical route. While
previous studies of MIF induction from LPS-stimulated
monocytes had mostly been performed in mouse cells, we
have established an experimental system that allows to quan-
titate LPS-induced MIF secretion from human THP-1 mono-
cytes. We demonstrate that LPS-regulated secretion of MIF is
fully functional in the absence of an intact ER/Golgi system.
Moreover, we provide evidence that ABCA1 transporters are
involved in the overall process of LPS-induced secretion of
MIF.
2. Materials and methods
2.1. Cell lines, reagents and antibodies
Human monocytic THP-1 cells were maintained in complete RPMI
1640 medium containing 10% fetal calf serum (FCS), 2 mM L-gluta-
mine, 100 U/ml penicillin and 100 Wg/ml streptomycin. RAW 264.7
mouse macrophages were maintained in complete DMEM medium
containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and
100 Wg/ml streptomycin. All cell culture media and reagents were
from Invitrogen/Life Technologies (Karlsruhe, Germany). Recombi-
nant human MIF (rMIF) and rabbit anti-mouse MIF polyclonal anti-
body were prepared as described previously [14]. Peroxidase-conju-
gated anti-rabbit IgG was used as secondary antibody and was
from Santa Cruz Biotechnology (Heidelberg, Germany). Alkaline
phosphatase-conjugated goat anti-rabbit IgG was from Pierce/KMF
(St. Augustin, Germany). Normal goat serum was from Invitrogen.
PNGase F was from New England Biolabs (Heidelberg, Germany).
All inhibitors used were from Fluka-Sigma-Aldrich Chemie GmbH
(Taufkirchen, Germany).
2.2. MIF secretion assay
THP-1 cells were synchronized for 3 h in RPMI 1640 medium
containing 1% FCS and 2 mM L-glutamine. Cells were washed once
and plated in the same medium at 1U106 cells per ml in 12-well
plates. For routine assays, inhibitors were added at the indicated
concentrations 45 min prior to stimulation with 10 Wg/ml LPS. Inhib-
itors were dissolved as suggested by the supplier. Solvents applied
were mostly organic solvents such as dimethylsulfoxide (DMSO)
and ethanol and therefore, control incubations with solvent alone
were included in all assays to exclude potential toxic e¡ects. All sol-
vents used were also probed directly for potential cell toxicity e¡ects
by performing lactate dehydrogenase (LDH) assays on cell incuba-
tions treated with solvent alone. These analyses showed that the sol-
vents did not cause any signi¢cant toxic e¡ects (see Table 1). Unless
stated otherwise, cells were collected after 4 h by centrifugation for
5 min at 400Ug and cell-free supernatants stored at 320‡C until
analysis by enzyme-linked immunosorbent assay (ELISA).
2.3. LDH activity assay
LDH activity was measured according to the recommendations of
the supplier (Roche Diagnostics, Mannheim, Germany). Brie£y, ac-
tivity was assayed by mixing 20 Wl cell-free supernatants and 980 Wl
assay bu¡er (7.6 mM sodium pyruvate, 0.2 mM NADH in 100 mM
potassium phosphate bu¡er, pH 7.0). Absorbance was read at 340 nm
for 5 min and activity expressed in mU/ml.
2.4. MIF and TNF ELISAs
Cleared lysates were prepared by lysing the cells in 25 mM Tris^
phosphate bu¡er, pH 7.8, 2 mM dithiothreitol, 2 mM bis-1,2-diami-
nocyclohexane-N,N,NP,NP-tetraacetic acid (CDTA), 10% glycerol, and
1% Triton X-100 for 20 min on ice followed by centrifugation for 10
min at 13 000 rpm and 4‡C. Cell-free supernatants were assayed di-
rectly, while cell lysates were diluted at an appropriate ratio in Tris-
bu¡ered saline (TBS) (20 mM Tris^HCl, pH 7.3, 150 mM NaCl)
containing 0.1% bovine serum albumin (BSA) and 0.05% Tween 20.
Human MIF was assayed by a sandwich ELISA using the MAB289
capture and BAF289 detection antibody from RpD Systems (Wies-
baden, Germany) according to the manufacturer’s instructions.
Brie£y, Immulon II microtiter plates (Dynex Technologies, Denken-
dorf, Germany) were coated with the capture antibody (2 Wg/ml in
phosphate-bu¡ered saline, PBS) overnight, washed and blocked with
blocking bu¡er containing 1% BSA and 5% sucrose in PBS for 1 h.
100 Wl aliquots of the cell supernatants or diluted lysates were added
to each well and incubated for 2 h. The wells were washed and incu-
bated with the biotinylated BAF289 antibody (0.2 Wg/ml in TBS,
containing 0.1% BSA and 0.05% Tween20) for 2 h. This was followed
by the addition of peroxidase-conjugated streptavidin (Roche Molec-
ular Biochemicals, Mannheim, Germany) for 20 min. Following ad-
dition of TMB substrate solution (Pierce/KMF), immune complexes
were quanti¢ed in a standard microtiter plate reader. MIF concentra-
tions were calculated by extrapolation from a standard curve (range
0^100 ng/ml; sensitivity 19 pg/ml) using bacterially expressed rMIF
[27] as a standard.
TNF was quanti¢ed by RpD System’s capture antibody MAB610
and detection antibody BAF210 using essentially the same protocol as
above except that the capture antibody was used at 4 Wg/ml. TNF
concentrations were calculated by extrapolation from a standard
curve (range 0^1000 pg/ml, sensitivity 5 pg/ml) using recombinant
TNF (RpD Systems).
2.5. N-glycosylation analysis
THP-1 cells were stimulated with 10 Wg/ml LPS for 4 h and RAW
264.7 cells were stimulated with 100 ng/ml LPS for 12 h. Cells were
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then lysed in RIPA bu¡er (50 mM Tris^HCl, 150 mM NaCl, 1%
Igepal CA-630, 0.5% deoxycholate, 0.1% SDS, 2 mM EDTA, pH
7.5) and cleared by centrifugation at 13 000Ug. 10 Wg cell lysates,
100 Wg cell-free supernatants, 10 ng rMIF and 5 ng anti-MIF IgG
were denatured in bu¡er containing 0.5% SDS and 1% L-mercapto-
ethanol for 10 min at 100‡C. Samples were then incubated in 50 mM
sodium phosphate bu¡er, pH 7.5, containing 1% NP-40 in the pres-
ence or absence of 100 NEB units PNGase F (New England Biolabs)
overnight at 37‡C. The reaction was stopped by adding 2U Laemmli
electrophoresis bu¡er and heating to 95‡C for 3 min. The samples
were separated by denaturing SDS^PAGE. For comparison, N-glyco-
sylated MIF was produced in B-16 melanoma cells engineered to
stably express a fusion protein containing the interleukin-2 (IL-2)
N-terminal signal peptide linked to the mouse MIF gene (kindly pro-
vided by Dr. Glen Drano¡, Dana-Farber Cancer Institute and Har-
vard Medical School, Boston, MA, USA). IL-2-signal peptide^MIF
fusion protein expressed and secreted in these cells was analyzed by
PNGase F treatment and Western blotting against MIF using the
protocols described above, except that digestion was performed with
1000 NEB units for 1 h.
2.6. SDS^PAGE and Western blot analysis
Samples were separated on 18% or 4^12% NuPAGE (for MIF
analysis) and 10% (for IgG analysis) SDS^PAGE gels, transferred
to nitrocellulose, and immunoblotting analysis performed essentially
as described previously [14]. The blot was incubated at room temper-
ature for 2 h with the appropriate primary antibody as speci¢ed in the
¢gure legend, and diluted 1:1000 in blocking bu¡er. Incubation with
the corresponding peroxidase-conjugated secondary antibody was per-
formed at room temperature for 2 h at a dilution of 1:10 000 in
blocking bu¡er. As ECL reagent, SuperSignal West Dura (Pierce)
was used.
2.7. In vitro translation into microsomes
Human MIF cloned into pET11b as described previously [28] was
used as the encoding plasmid and was linearized by digestion with
EcoRI (New England Biolabs) and the cDNA was transcribed using
the Ribomax Large Scale RNA Production System T7 (Promega,
Mannheim, Germany). The human MIF transcript or the yeast
K-factor glycosylation control mRNA was then translated for
90 min at 30‡C using the Flexi Rabbit Reticulocyte Lysate System
with or without canine pancreatic microsomal membranes in the pres-
ence of RNAsin ribonuclease inhibitor (all from Promega) and ProM-
ix L-[35S] in vitro labeling mix (Amersham Biosciences, Freiburg, Ger-
many). The reaction was stopped by adding 2U Laemmli
electrophoresis bu¡er and heating for 3 min at 95‡C. The samples
were separated on an 18% SDS^PAGE gel and analyzed as described
above.
Fig. 1. MIF is not glycosylated and does not enter microsomes. A: Amino acid sequence of human MIF. MIF does not have a classical N-ter-
minal or an internal hydrophobic signal sequence. The two potential N-glycosylation sites of MIF are underlined. The Met-1 residue is post-
translationally processed in both bacteria and mammalian cells. B: N-glycosylation analysis of MIF expressed and secreted in LPS-stimulated
monocytes/macrophages. Immunoblot analysis of IgG, rMIF, THP-1 and RAW 264.7 cell lysates (CL) and supernatants (SN) after incubation
with (+) or without (3) PNGase F. Left panel, samples were separated on 10% SDS^PAGE and probed with anti-IgG antibody. Right panel,
samples were separated on 16.5% Tricine^SDS^PAGE and probed with anti-MIF antibody. C: Autoradiograph of [35S]-labeled, in vitro-trans-
lated human MIF (middle panel) or yeast K-factor protein (right panel) in the presence (+) or absence (3) of microsomal membranes. Secreted
MIF expressed as an IL-2 signal peptide/MIF fusion construct in B-16 melanoma cells and concentrated from the cell supernatant (B16-MIF)
migrates at 24 and 17 kDa (left panel), as evidenced by PNGase F digestion and Western blotting with anti-MIF antibody. The positions of
relevant molecular weight markers are indicated.
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3. Results
3.1. MIF does not enter the classical ER/Golgi pathway, but is
e¡ectively secreted from monocytes/macrophages following
LPS stimulation
Numerous reports have shown that MIF is e¡ectively and
speci¢cally secreted from several cell types following stimula-
tion. This is somewhat surprising because MIF does not have
an N-terminal signal peptide (Fig. 1A). MIF from bovine liver
cell lysates does not become post-translationally N-glycosylat-
ed although two potential N-glycosylation sites are present in
the MIF cDNA sequence [28] (Fig. 1A), but N-glycosylation
of secreted MIF had not been investigated in immunologically
stimulated monocytes/macrophages. We ¢rst wanted to ana-
lyze whether MIF expressed and secreted from LPS-stimu-
lated monocytes/macrophages was also not N-glycosylated
as seen for the liver MIF. Human monocytes (THP-1) and
mouse macrophages (RAW 264.7) were stimulated with LPS
and intracellular and secreted MIF was probed for N-glyco-
sylation by PNGase F treatment and SDS^PAGE/Western
blotting analysis (Fig. 1B). While PNGase F treatment of
immunoglobulin G (IgG), a known N-glycosylated protein,
resulted in a band shift, with the faster migrating band cor-
responding to the size of deglycosylated IgG, no PNGase F
e¡ect whatsoever was observed when the MIF-containing
monocyte/macrophage cell lysates and supernatants were an-
alyzed by electrophoresis and anti-MIF Western blot. This
con¢rmed that MIF expressed and secreted in LPS-induced
monocytes/macrophages was in fact not N-glycosylated. To
rule out the possibility that potential inhibitory processes oc-
curring in immune-stimulated monocytes/macrophages could
interfere with the transport of MIF across the ER membrane,
we next tested whether in vitro transcribed and translated
(IVT) human MIF was able to enter microsomal vesicles
and to become N-glycosylated therein. MIF also did not enter
the microsomal vesicles, as evidenced by a lack of N-glycosyl-
ation in this in vitro system (e.g. its unchanged molecular size
ofV12.5 kDa, Fig. 1C). By contrast, yeast K-factor, a protein
known to be N-glycosylated in the ER/Golgi passage, and
frequently used as a standard for N-glycosylation in IVT sys-
tems, entered the ER vesicles and was N-glycosylated, as evi-
denced by a band at 30 kDa that appeared in the presence of
microsomes in addition to the 19 kDa band. N-glycosylation
of MIF would have resulted in a bis-N-glycosylated protein
species with an apparent size of 24 kDa protein. Also, an
apparently mono-N-glycosylated form with a band size of
17 kDa can be observed. This was demonstrated by PNGase
F digestion and Western blotting of cell supernatants from
B-16 melanoma cells that had been constructed to stably
express an IL-2-signal peptide^MIF fusion protein targeting
MIF into the ER/Golgi pathway (Fig. 1C).
THP-1 monocytes were chosen as an LPS-inducible mono-
cyte cell line to study MIF secretion by MIF-speci¢c ELISA.
MIF was potently and speci¢cally released from THP-1
monocytes following stimulation with 10 Wg/ml LPS (Fig.
2A). Speci¢city of MIF release was veri¢ed by MIF Western
blot analysis (Fig. 2B). MIF secretion was fast, with the peak
of MIF secretion occurring by 2^4 h post LPS induction.
Signi¢cant LPS-stimulated release was seen up to 8 h. LPS-
stimulated MIF secretion was not due to cell stress or cell
death, as only a minor portion of cells stained positively for
Trypan blue (6 5%) and because no signi¢cant LDH activity
was detected in the cell supernantants (Table 1). Uninduced
release of MIF occurred only to a low extent (Fig. 2A). LPS
stimulation of MIF secretion was concentration-dependent
(Fig. 2C). Measurable release of MIF was seen with 0.1 Wg/
ml of LPS; however, best results were obtained with 10 Wg/ml
of LPS, which is why subsequent analyses were performed
using this LPS concentration.
3.2. Inhibitors of the classical ER/Golgi secretion pathway as
well as a variety of other protein secretion inhibitors do not
interfere with MIF secretion from LPS-stimulated THP-1
cells
To further probe whether any parts of the ER/Golgi path-
way would act to mediate stimulated secretion of MIF, we
next analyzed the e¡ects of the inhibitory compounds brefel-
din A (BFA) and monensin on the secretion of MIF from
LPS-treated THP-1 cells. Both compounds are typical inhib-
itors of the ER/Golgi secretion pathway. BFA inhibits trans-
port of secretory proteins between the ER and the cis-Golgi
[29], whereas monensin predominantly blocks the protein
transport at the trans-Golgi apparatus cisternae [30]. Fig.
3A shows that monensin only marginally inhibited LPS-stimu-
lated MIF secretion, when added at 0.5 Wg/ml, while no re-
duction was seen with 5 Wg/ml monensin. By contrast, the
secretion of the cytokine TNF, which is known to be secreted
by the ER/Golgi pathway, was completely abolished in the
Table 1
LDH activity assays of the inhibitor studies and solvent control incubations
Solvent, positive control bu¡er,
stimulus
LDH activitya in
cell supernatant [mU/ml]
Classical pathway inhibitors/
other agents
LDH activitya in cell supernatant
[mU/ml]
PBS 6.0 Monensin 32.2
0.5% EtOH 2.0 Brefeldin A 20.1
0.01% NaOH in EtOH 6.0 CCCH 50.2
0.1% DMSO 10.0 Cycloheximide 21.4
1U106 lysed cells 221.1 Methylamine 26.1
A23187 24.1
ABC transporter inhibitors LDH activitya in cell supernatant
[mU/ml]
Verapamil 60.3
Benzamidin n.d.
Phenantrolin n.d.
Glyburide 32.2
Probenicide n.d.
aLDH activity assay was performed as described in Section 2. Data are the means of four measurements.
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presence of monensin (Fig. 3B). Of note, while BFA led to a
V30% decrease in TNF secretion (Fig. 3B), this reagent not
only did not inhibit the secretion of MIF, but even led to an
apparent stimulation of MIF secretion up to 150% of the
e¡ect seen for LPS alone (Fig. 3A). Overinduction by BFA
Fig. 2. Secretion of MIF from LPS-stimulated THP-1 monocytes.
A: Time course of the secretion of MIF following incubation of
cells with and without LPS. Cells were treated with LPS (10 Wg/ml)
(black bars) or PBS (gray bars), supernatants collected at the indi-
cated time intervals and assayed for MIF concentration by ELISA.
Results are expressed as mean values TS.D. of triplicate measure-
ments from one representative experiment (n=3) of a total of three
kinetics performed. B: Western blot veri¢cation of LPS-induced se-
cretion of MIF from THP-1 cells. Cells were treated with LPS (10
Wg/ml), PBS (bu¡er control), or DMSO (solvent control) for 4 h,
supernatants collected at the indicated time intervals and assayed by
NuPAGE electrophoresis and immunoblotting with MIF-speci¢c
antibody. Bands were subjected to semi-quantitative analysis using
densitometry with NIH image and numbers shown indicate relative
pixel intensities. C: LPS concentration dependence. Cells were
treated with LPS at the indicated concentrations, supernatants col-
lected after 4 h and assayed for MIF concentration by ELISA. Re-
sults are expressed as mean valuesT S.D. of triplicate measurements
from one dose response (n=3) of a total of three experiments.
Fig. 3. MIF secretion is neither inhibited by the classical pathway
inhibitors brefeldin A (BFA) and monensin nor by typical other
protein secretion inhibitors. A,B: E¡ect of BFA and monensin (ab-
breviated: mon.) on the secretion of MIF from LPS-stimulated
THP-1 cells. Human MIF and TNF ELISAs of THP-1 supernatants
after stimulation for 4 h with 10 Wg/ml LPS in the absence or pres-
ence of the indicated concentrations of BFA and monensin. The
concentration of secreted MIF (panel A) or TNF (panel B) as mea-
sured by ELISA is shown. Results are expressed as mean val-
ues TS.D. of triplicate measurements from three independent experi-
ments (n=9). Control incubations with the corresponding solvents
alone (solv. conc.) or inhibitor alone (for example, 5 Wg/ml monen-
sin/no LPS) showed that the solvents did not have inadvertent ef-
fects. C: E¡ect of the endocytosis inhibitor methylamine (MA, 10
mM), the calcium ionophore A23187 (1 Wg/ml), the protein synthesis
inhibitor CHX (2 Wg/ml), the energy uncoupling agent CCCH (10
WM), and an 18‡C temperature block (control at 37‡C) on MIF se-
cretion from LPS-stimulated THP-1 cells. Results are expressed as
mean valuesT S.D. of triplicate measurements from two (n=6; for
temperature, CHX, and A23187) or three (n=9; for CCCH and
MA) independent experiments. Control incubations with the corre-
sponding solvents alone (solv. conc.) or the inhibitor alone (for ex-
ample, CCCH con.) showed that the solvents or inhibitors did not
have inadvertent e¡ects. Stastistical signi¢cance was always deter-
mined for the ‘LPS+inhibitor’ data sets in comparison to the corre-
sponding ‘LPS’ group by unpaired Student’s t-test. Signi¢cant di¡er-
ences (P6 0.05) are indicated by an asterisk on the ‘LPS+inhibitor’
bars. For the temperature block experiment, the 18‡C data set is
compared with that of the 37‡C treatment.
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was not due to non-speci¢c cell death, as BFA only led to
background LDH activity levels in the cell supernatants (Ta-
ble 1). Next, a number of other typical inhibitors for which an
interference with cellular transport processes had been re-
ported [24] were applied to begin to distinguish and poten-
tially identify the export pathway taken by MIF. Fig. 3C
shows that neither the protein synthesis inhibitor cyclohexi-
mide (CHX), the respiratory chain uncoupling reagent car-
bonyl cyanide m-chlorophenyl hydrazone (CCCH), the endo-
cytosis inhibitor methylamine (MA), nor the calcium
ionophore A23187 inhibited MIF secretion. Rather, stimu-
lated LPS-induced secretion of MIF was even superinduced
Fig. 4. Inhibitors of ABC transporters inhibit the secretion of MIF. A: Quantitative assessment of the e¡ects of several ABC transporter inhib-
itors on the secretion of MIF from LPS-stimulated THP-1 cells. Human MIF ELISA of THP-1 supernatants stimulated with 10 Wg/ml LPS in
the absence or presence of ABC transporter activity inhibitors. BSP (4 WM) and DIDS (500 WM) exhibited non-speci¢c e¡ects on the release of
MIF (bars not shown; see text). Vera was added at a concentration of 15 WM, benzamidine HCl (Benz) at 20 WM, Phen at 50 WM, glyburide
(Gly) at 2.5 WM, and probenicide (Prob) at 2 WM. Results are expressed as mean valuesT S.D. of triplicate measurements from three indepen-
dent experiments (n=9), except for Vera and benzamidine, with n=6 measurements from two independent experiments. Control incubations
with the corresponding solvents alone (solv. con.) or the inhibitor alone (for example, Benz con.) showed that the solvents or inhibitors did not
have inadvertent e¡ects. B: E¡ect of glyburide on the secretion of MIF as compared to its e¡ect on TNF secretion. A concentration depen-
dence as indicated is shown. Results are expressed as mean valuesT S.D. of triplicate measurements from three independent experiments (n=9).
Control incubations with the corresponding solvents alone (solv. con.) or the inhibitor alone (for example, 2.5 WM glyburide/no LPS) showed
that the solvents or inhibitors did not have inadvertent e¡ects. C: Same as panel B, except that cells were treated with probenicide instead of
glyburide. Stastistical signi¢cance was always determined for the ‘LPS+inhibitor’ data sets in comparison to the corresponding ‘LPS’ group by
unpaired Student’s t-test. Signi¢cant di¡erences (P6 0.05) are indicated by an asterisk on the ‘LPS+inhibitor’ bars.
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by some of these agents. CHX and CCCH led to a slight but
signi¢cant overstimulation as compared to the e¡ect of LPS
alone. The CHX e¡ect, while small, could indicate that short-
living proteins produced by de novo protein synthesis are not
necessary for LPS-stimulated MIF secretion. Overinduction
by CCCH was more pronounced but since CCCH incubations
showed an increased LDH activity in the cell supernatants
(Table 1), no further conclusions may be drawn from this
¢nding. A23187 led to a marked (two-fold) increase of LPS-
induced MIF secretion. A23187, among other e¡ects, can in-
duce calcium-dependent exocytosis, indicating that LPS-in-
duced MIF secretion in monocytes could be a calcium-depen-
dent process. Except for CCCH, none of these inhibitors led
to a non-speci¢c release of LDH (Table 1). Applying an 18‡C
temperature block led to a signi¢cant reduction of LPS-stimu-
lated MIF secretion of approximately 50%. An 18‡C temper-
ature block is known to interfere with transport processes
through the Golgi passage [31].
3.3. Secretion of MIF from LPS-stimulated THP-1 monocytes
is markedly blocked by the ABC transporter inhibitors
glyburide and probenicide
For IL-1L, evidence was obtained that multidrug resistance
proteins (MDR) of the ATP binding cassette (ABC) trans-
porter subfamily 1 (ABCA1) are involved in non-classical ex-
port of this cytokine [32]. As ABC transporters had also been
implicated in the non-classical secretion of FGF2 [33], we next
tested whether addition of inhibitors of ABC transporters
interfered with the non-classical secretion of MIF. LPS-stimu-
lated THP-1 cells were preincubated with various inhibitors
reported previously to block ABC transporter- or P-glycopro-
tein-mediated pathways (Fig. 4A).
Except for verapamil (Vera), which led to a slight elevation
in secreted LDH levels, the ABC transporter inhibitors were
not toxic for the THP-1 cells (Table 1). Bromosulfalein (BSP)
and 4,4P-diisothiocyanato-stilbene-2.2P-disulfonic acid (DIDS)
led to an LPS-independent stimulation of MIF release from
THP-1 cells, an observation which made it di⁄cult to further
evaluate the potential secretion-interfering e¡ect of these com-
pounds. The P-glycoprotein inhibitor Vera and 1,10-phenan-
trolin (Phen) slightly inhibited LPS-stimulated MIF secretion,
but these e¡ects were not signi¢cant. Benzamidine did not
exhibit any inhibitory e¡ect.
Most strikingly, these scouting experiments indicated that
the putative ABCA1 inhibitors glyburide and probenicide
markedly inhibited MIF secretion (Fig. 4A). We therefore
analyzed the e¡ect of these two compounds further. Glyburide
inhibited LPS-induced secretion of MIF from THP-1 cells
over a wide concentration range (Fig. 4B). Strongest inhibi-
tion was observed at a concentration of 5 WM. At lower con-
centrations of glyburide, the inhibitory e¡ect was reduced,
however, at 0.5 WM, glyburide inhibition was V50%. In con-
trast, as previously noted [32], glyburide inhibited the classical
secretion of TNF to a much lesser extent (Fig. 4B) and also
did not lead to marked cell toxicity (Table 1). The glyburide
¢ndings were con¢rmed by the concentration curves with pro-
benicide. Fig. 4C shows that probenicide strongly and concen-
tration-dependently inhibited the secretion of MIF, while ab-
solutely no e¡ect of probenicide could be detected with regard
to TNF secretion. Neither treatment with glyburide nor pro-
benicide led to a reduction in the intracellular protein concen-
tration and synthesis rate of MIF (data not shown), demon-
strating that these inhibitors did not a¡ect the de novo
synthesis of MIF. This further suggested that glyburide and
probenicide speci¢cally interfere with the non-classical export
of MIF.
4. Discussion
Non-classical export of a soluble mammalian secretory pro-
tein was ¢rst discovered 13 years ago [24]. Since then, several
proteins, including cytokines, growth factors, components of
the extracellular matrix, as well as certain enzymes and tran-
scription factors that were previously thought to only exhibit
intracellular functions were found to be e¡ectively secreted by
non-classical export pathways (reviewed in [25]). According to
the available evidence, no single transport pathway mediates
non-classical export, but several distinct export protein machi-
neries exist. Only for a few factors, including IL-1K, IL-1L,
and FGF-1, molecular entities involved in the secretion path-
way have been identi¢ed. For IL-1L, it appears from inhibitor
studies and antisense experiments [32,34] that the overall pro-
cess of secretion requires the function of an ABC transporter
protein. As glyburide, one of the inhibitors that was found to
inhibit IL-1L secretion, exerts speci¢city towards ABCA1
transporters and as anti-ABCA1 antisense oligonucleotides
reduce IL-1L secretion from macrophages [34], secretion of
this cytokine appears to be associated with the function of
an ABCA1 transporter, which is probably located within an
endolysosomal compartment [35]. FGF-1 appears to be ex-
ported as a multiprotein aggregate with cytosolic p40 domain
of the membrane protein synaptotagmin (p40 Syt1) and the
Ca2þ binding protein S100A13 [36^39]. A copper-mediated
oxidation and dimerization process of FGF-1 is required for
FGF-1 release and the unprocessed precursor form of IL-1K
represses stress-induced FGF-1 export [40]. A very recent pub-
lication elucidated the precise role of IL-1K in this process and
revealed molecular details of the export of IL-1K itself. Man-
dinova et al. [41] demonstrated that IL-1K is a copper-binding
protein and that stress-induced IL-1K release is copper-depen-
dent and associated with binding to S100A13, which also
binds copper. In addition, as shown previously for FGF-1
[42], a molten globule character was demonstrated for IL-1K
that could be critical for traversing the plasma membrane. As
IL-1 and FGF proteins share several striking structural sim-
ilarities and as eight of the currently identi¢ed 10 members of
the IL-1 family lack a signal peptide, it is likely that the
molecular mechanism of the secretion of several IL-1 family
members is similar to that of FGF-1 [41].
MIF is a key in£ammatory factor for which a role in sev-
eral disease states has been demonstrated [3]. However,
although discovered already 4 decades ago [26], the mecha-
nisms underlying the biological e¡ects of MIF are not yet well
understood. The signal transduction pathways of MIF have
remained ill-de¢ned [3]. Also, although speci¢c secretion of
MIF can be induced from several immune and non-immune
cells, the machinery mediating intracellular targeting and se-
cretion of MIF has remained unknown. Elucidation of the
secretion pathway of MIF would therefore be of high interest
and, should it turn out that MIF-speci¢c processes exist,
could give rise to novel therapeutic approaches aiming at
blocking the in£ammatory and disease-promoting properties
of this cytokine.
In this study, we have focused on studying the secretion
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pathway of MIF in immune-stimulated, i.e. LPS-induced,
monocytes, because LPS-induced MIF secretion is likely to
represent a (patho)physiologically relevant process [16]. We
provide direct evidence that MIF is not secreted by the ER/
Golgi pathway in these cells. Instead, we demonstrate that
MIF is secreted by non-classical export. Because the pharma-
cological substances glyburide and probenicide, which inter-
fere with ABC transporter function, strongly blocked MIF
secretion while having no e¡ect on MIF synthesis and turn-
over, we conclude that an ABC transporter is a critical com-
ponent required for the process of MIF secretion.
It had long been speculated that MIF could be secreted by
non-classical ways. MIF does not have an N-terminal signal
peptide, nor does it have apparent internal ER-targeting mo-
tifs [28]. Furthermore, while a cytosolic and nuclear localiza-
tion of MIF has been shown [14,21,22,43,44], Eickho¡ and
coworkers recently demonstrated that MIF occurred in
pinched-o¡ vesicles outside the epithelial cells in the lumen
of the epididymis, and that this localization was associated
with MIF secretion from these cells [20]. On the other hand,
the observation that MIF is localized within typical secretion
vesicles of endocrine cells such as ACTH-secreting pituitary
cells and insulin-secreting L-islet cells [17,45], could be in
agreement with a classical secretion pathway. The latter pos-
sibility may be supported by the study of Eickho¡ et al. [20],
who also observed the localization of MIF in vesicles in epi-
didymal epithelial cells. However, in such cells yet another
specialized secretion mechanism appears to exist, as a pinch-
ing-o¡ of MIF-containing exosomes and a direct transfer to
spermatozoa was detected. Also, MIF secretion is induced by
a pro¢le of immunological stimuli (i.e. TNF, IL-1, or LPS)
that is very similar to that of other cytokines that are secreted
by classical pathways. Thus, indications for both a more clas-
sical and non-classical mode of MIF secretion had been col-
lected. However, no systematic study had yet addressed this
question in a physiologically relevant cellular model.
We ¢rst excluded the possibility that MIF would enter the
ER/Golgi system by a so far unknown mechanism. We show
that MIF does not enter microsomes in vitro, is not glycosy-
lated in monocytes or macrophages in vivo, and that MIF
secretion from monocytes is not inhibited by inhibitors of
the classical pathway such as BFA or monensin. The over-
stimulatory e¡ect on MIF secretion seen for BFA was remi-
niscent of the e¡ect of this inhibitor on the secretion of IL-1L
[24]. Other pharmacophores, including the protein synthesis
inhibitor CHX, the energy uncoupling reagent CCCH, the
endocytosis inhibitor MA, and the Ca2þ ionophore A23187,
had either no e¡ect or also overinduced MIF secretion. To-
gether, these data unanimously suggested that MIF is secreted
by a non-classical pathway.
Di¡erent non-classical export pathways exhibiting di¡erent
molecular machineries have been suggested to exist. These
include heat shock-inducible pathways in connection with
mechanisms involving protein aggregate formation with p40
Syt1 and S100A13, ABC transporter-mediated pathways, pro-
cesses dependent on tubulin-mediated transport processes,
and yet other pathways (see above and summarized in [25]).
We addressed the possibility that non-classical MIF secretion
could depend on ABC transporter activity, because the export
of two other non-classically secreted cytokines, IL-1L and
FGF-2, had already been found to be associated with ABC
protein function. Of the corresponding array of inhibitors
tested on LPS-induced MIF secretion in monocytes, glyburide
and probenicide markedly block MIF secretion in a concen-
tration-dependent fashion. This leads us to conclude that se-
cretion of MIF requires the function of ABC transporter pro-
teins for at least one step during the secretory process. As
glyburide and probenicide have been suggested to be some-
what speci¢c in their inhibitory potential for the ABCA1
transporter subclass, we conclude that this sub-category of
transporters is involved.
There are at least three potential mechanisms by which
ABCA1 transporters could be involved in MIF export. As
ABCA1 has been suggested to serve as a regulator of vesicular
transport between the TGN and the plasma membrane [46],
these proteins could either mediate the entry of MIF into
post-Golgi vesicles or could promote MIF vesicle transport.
In the latter case, transport of MIF across the vesicle mem-
brane would have to be mediated by an as yet unidenti¢ed
protein. A possible candidate may be the vesicle-tethering
protein, p115 [47]. Of note, ABCA1 was also proposed to
function as a channel protein or so-called £oppase [46]. How-
ever, although the non-classically secreted factors FGF-1 and
IL-1K have been suggested to traverse the plasma membrane
by direct non-vesicular processes [38,39,41], it is unlikely that
MIF is directly transferred across the plasma membrane in an
ABCA1-mediated fashion, as the export mechanism for MIF
seems to di¡er from that of FGF-1 and IL-1K. Also, it is
currently unclear whether the £oppase activity of ABCA1
applies to proteins [48]. Lastly, the e¡ect of ABCA1 on
MIF export could be an indirect transporter function.
ABCA1 proteins can act to translocate lipids, a process that
could lead to an altered membrane structure that in turn
could inhibit the proteinaceous and possibly membrane-
bound machinery mediating translocation of MIF.
The conclusions drawn in this study that were derived
mainly from the application of the pharmacological inhibitors
will have to be con¢rmed by additional biochemical studies,
such as MIF^ABCA1 interaction studies or the use of mono-
cytes/macrophages from ABCA1 knock-out mice. In such fu-
ture studies, the possibility that MIF export is mediated by
ABC transporters other than ABCA1 will also need to be
addressed, because glyburide also a¡ects ABCC7 function
[49] and probenicide has been reported to interfere with sev-
eral ABCC proteins [50].
Our data suggest that the export pathway taken by MIF
could be similar to that suggested to be used by IL-1L. Similar
export mechanisms for MIF and IL-1L could mirror the sim-
ilar pro-in£ammatory spectrum of activities that these two
cytokines share [51]. MIF also shares a potent angiogenic
activity pro¢le with the IL-1 type proteins [7]. However, a
pro-angiogenic activity is especially exerted by the FGFs,
which together with IL-1K seem to be released by a distinct
mechanism. It is of note in this context that MIF is also
e⁄ciently secreted by heat and redox stress (J. Bernhagen,
unpublished and [52]). In contrast, the mechanisms of LPS-
stimulated secretion for IL-6, another typical pro-in£amma-
tory cytokine, appears to be clearly di¡erent from that of
LPS-stimulated MIF secretion [53]. MIF and Trx share sev-
eral functional homologies with respect to their thiol-protein
oxidoreductase activities and cytokine e¡ects [3]. Trx, like
MIF, is secreted by non-classical pathways [54]. However,
although MIF and Trx share intruiging functional similarities
as cytokines [25] and share several features of their export
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pathways, it is unclear whether the mechanisms behind their
non-classical export pathways are similar. While IL-1L and
Trx secretion is inhibited by MA [24,54], this reagent did
not interfere with the export of MIF. ABCA1 inhibitors in-
terfere with the secretion of MIF and IL-1L, but do not a¡ect
Trx secretion.
Together, our study provides the ¢rst mechanistic evidence
that MIF is secreted by a non-classical pathway and suggests
that this pathway is dependent somehow on ABCA1 trans-
porter function. Thus, these ¢ndings are important for future
molecular studies and o¡er a ¢rst basis for the investigation of
potential therapeutic approaches targeting the MIF secretion
process.
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